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There is growing interest in the potential and use of extracellular vesicles (EVs) for a range of 
diagnostic and therapeutic applications. EVs have been shown, in some instances, to mediate 
the regenerative effects elicited by stem cell therapies. As such, they are being studied to 
identify the extent to which these extracellular bodies can be employed a therapeutic entity 
and significant R&D activity is underway to further understand their clinical and commercial 
potential. However successful translation will first require further characterisation and 
standardisation of EV production, was well asaddressing some of the major challenges 
associated with their reproducible manufacture. This includes the capacity to produce EVs at 
a scale that is both clinically and commercially effective. This article will highlight some of 
the bioprocessing and manufacturing considerations and challenges associated with the 
standardized production of EVs.     
 
Introduction 
The next generation of therapeutics will employ the use of whole cells, such as human stem 
cells or gene-modified cells, for the treatment of acute and chronic conditions. This has 
resulted in significant research and development activity to establish large-scale production 
platforms for human stem cells, both pluripotent (e.g. embryonic and induced pluripotent) 
and multipotent (mesenchymal and haematopoietic). Whilst there have been numerous 
clinical trials involving the use of human mesenchymal stem/stromal cells (MSCs) and 
general recognition the cells are safe to administer and elicit a therapeutic response, it is 
unclear as to the underlying mechanism by which the cells induce a therapeutic effect. 
Evidence suggests that rather than engrafting and integrating with the host tissue as originally 
expected, these multipotent cells primarily exert their therapeutic effects via the secretion of 
trophic factors and extracellular vesicles (EVs) into the surrounding environment [1, 2]. As 
such, there has been growing interest in the role of EVs, with these secreted extracellular 
bodies potentially representing the active pharmaceutical agent for MSCs. Studies have been 
conducted demonstrating the therapeutic potential of EVs across a wide range of different 
clinical applications including inflammation, cardiovascular diseases, wound healing and 
hypertension [3-5]. In view of this potential, efforts are now being undertaken to explore the 
standardization and manufacturability of EVs at a scale that is both clinically and 
commercially relevant. 
 
1. The role of extracellular vesicles    
Amongst the complex mixture of factors comprising the MSC secretome, vesicles are 
considered particularly significant since they have been shown to mediate endocrine and 
paracrine signalling in a number of tissues [6]. Vesicles can be differentiated by their size, 
molecular content and mechanism of biogenesis. Within the majority of biofluids studied thus 
far, there exists a heterogeneous mixture of vesicles that range in size from 30-2000nm 
(Table 1). They fall into three main categories, which include: (1) apoptotic bodies, (2) 
shedding- or micro-vesicles and (3) exosomes (Table 1). From a therapeutic perspective, 
shedding vesicles and exosomes have received considerable attention and we shall henceforth 
refer to them collectively as EVs. As a consequence of their biogenesis, the lumen of each 
vesicle is loaded with a complex mixture of proteins and nucleic acids derived from the 
plasma membrane and cytoplasm. As such, the biological profiles of EVs mirror the parental 
cells from which they originated and much attention has been directed toward deciphering the 
molecular signature of EVs and using this information to identify biomarkers for the 
prediction of a variety of diseases and conditions including various forms of cancer [7]. 
However, it is becoming apparent that there is also an opportunity to exploit the natural 
communicative roles of these nano-particles for regenerative applications. To date, these 
small delivery vehicles have been implicated in a number of physiological processes that 
have long been of interest to the tissue engineering community and include angiogenesis, 
ossification, matrix remodelling and immunity [8]. As such, the considerable value of EVs as 
an acellular source of valuable biological factors that may be combined with scaffolds, or 
indeed used in isolation, to bring about a therapeutic benefit is becoming increasingly evident.  
 
Exosomes 30-150nm 
Endosomal vesicles that arise 





Ectosomal vesicles that arise 
from outward blebbing of the 
cell membrane 
Apoptotic bodies 50-2000nm 
Derived from cells 
undergoing apoptosis 
Table 1. Detailing the three major vesicle subtypes generated by cells and found within 
culture medium and bodily fluids such as plasma, urine and saliva. 
There are considerable advantages in a shift towards an EV-based approach to regenerative 
medicine when compared with current cell-based approaches. Perhaps the most appealing 
prospect is that EVs can be fully characterised before administration with no risk of 
transformation or immunogenicity (at least for stem cell-derived exosomes). The lack of 
immunogenicity is significant, as it means that like MSCs, the EV source does not strictly 
have to be autologous. The presence of a bilipid membrane that confers added stability within 
the circulation combined with a natural homing capacity can be exploited to stably deliver 
therapeutic molecules to damaged or diseased sites within the body. The cell-derived lipid 
membrane also allows for simple and effective loading of EVs with molecules such as RNAs 
to enhance their therapeutic efficacy, while their protein component limits rapid clearance 
from the circulation [9]. The natural physiological role of these small particles in cell-cell 
communication, both local and distant, means that they are naturally tailored to for drug 
delivery, and as such lend themselves to the delivery of a variety of molecular factors to 
promote tissue regeneration. If the mode of action (MoA) is established and EVs can be 
reproducibly manufactured at scale, they have the potential to make a significant impact as a 
biologic.  
 
2. Clinical and commercial applications of EVs 
To date several clinical trials have sought to evaluate the efficacy of EV-based therapies. The 
majority of trials have applied EVs as anti-cancer agents, where EVs isolated from patients 
were pre-activated or administered in combination with anti-tumour peptide antigens raised 
against the cancer cells and then reintroduced to patients to initiate an immune response that 
specifically targeted the tumour. Such an approach has been applied to target metastatic 
melanoma [10], colorectal cancer [11] and non-small cell lung cancer [12]. These trials have 
shown initial promise with prolonged tolerance to EV administration reported and only mild 
inflammatory responses documented as a side effect. 
 
From a regenerative perspective, the number of EV-based clinical studies is steadily 
increasing as a greater understanding of the role EVs play in a regenerative context is 
developed. The significant regenerative effects of MSC-derived exosomes first came to the 
attention of the scientific community in 2010 when they were successfully applied in a 
murine model of myocardial ischaemia/reperfusion injury, promoting neoangiogenesis with a 
subsequent reduction in the area of infarct-related damage [13]. Subsequent studies have 
confirmed that the positive effects of stem cell therapies following ischaemia are largely a 
result of vesicles that orchestrate regeneration through the delivery of a cargo of biological, 
such as micro-RNAs that include miR-146a [14].  
 
Most recently, a phase I clinical trial has been established to investigate the effects of EV-rich 
plasma for enhanced cutaneous wound healing (NCT02565264). Platelet-rich plasma (PRP) 
has long been observed to provide significant therapeutic benefits for a multitude of ailments 
including chronic tendon injury, fractures and sports-related muscle injury. However, due to 
donor-variation and a lack of understanding of the specific MoA, PRP is difficult to 
standardise. Exosomes derived from PRP have previously been shown to deliver many of the 
principal growth factors thought to be, in part, responsible for the therapeutic effects of PRP 
[15]. At present, to the authors’ knowledge, this represents the only active clinical trial 
applying EVs for the purpose of tissue healing/regeneration. 
 
In addition to the aforementioned clinical trials, EVs have also been applied with successful 
outcomes in animal models of acute kidney toxicity [16]; neurological disorders such as 
multiple sclerosis [17] and sciatic nerve injury [18]; and gastrointestinal diseases such as 
induced colitis [19] and drug-induced inflammatory bowel disease [20]. Despite the relatively 
recent emergence of EVs as a potential therapeutic intervention, there are now multiple 
companies established with a focus on commercialising EVs for clinical and/or diagnostic use 
(Table 2). These include EVs from a range of different cell sources and for the treatment of a 
range of different clinical indications.  
 
Company Cell source 
Capricor Therapeutics Cardiosphere-derived cell 
Codiak Biosciences Mesenchymal stem cells 
Creative Medical Technologies Holdings 
inc. 
Amniotic fluid-derived stem 
cells 
Evox Therapeutics Dendritic cells 
Exogenus Therapeutics Umbilical cord blood 
Exosome Diagnostics Serum/plasma and urine 
samples 
Exosome Sciences Plasma samples 
Exosomics Siena SpA Prostate and colorectal cancer 
cells 
Kimera Labs Amniotic fluid-derived stem 
cells 
ReNeuron CTX neural stem cell 
RoosterBio Mesenchymal stem cells 
 Table 2. Companies involved in EV R&D for therapeutic or diagnostic applications  
 
3. Bioprocessing and manufacture of EVs  
Whilst the clinical utility of EVs in a regenerative context is becoming more apparent, there 
are however numerous challenges to be addressed before EVs can represent a real clinical 
alternative. These include reproducibility and isolation, storage, scalability (methods for mass 
production required to achieve clinical scale), characterization, safety and regulation.  
 
3.1 Reproducibility and isolation 
Reproducibility is dependent on several factors which begin at the donor and cellular level. 
Since the properties of EVs is dependent on the cells from which they originate and the 
conditions in which these cells are maintained, it is of critical importance that these variables 
are standardised to provide a reproducible population of EVs that elicit an optimal therapeutic 
effect. Donor to donor variation is likely to impact on the clinical efficacy of a particular EV 
therapy. In order to reduce the risk of variation it is important that the MoA of each EV 
therapy is understood so that it can be standardized and its therapeutic effects reproducible.  
Perhaps one of the most pertinent questions within the field of extracellular vesicles is how 
these valuable biological particles can be isolated at scale in a way that retains functionality 
and minimises the inclusion of non-vesicular contaminants, such as membrane fragments and 
extracellular proteins. EVs are most typically characterised based on their size and 
protein/lipid content. Current isolation methods have varying influence on the recovery of EV 
protein and RNA yield and modern solutions will likely be required to generate clinical grade 
EVs [21, 22]. Many recent examples have been published describing the merits and 
disadvantages of several distinct methods for the isolation of EVs from a diverse range of 
samples, which includes culture medium, urine, plasma and other body fluids [23].  
Of the multitude of isolation methods reported in the literature, differential ultracentrifugation  
remains the oldest and most widely applied method. This technique selectively sediments 
components of interest based on their size and density. However, ultracentrifugation often 
results in a high degree of variation [24]. Furthermore, it is a lengthy process that provides 
relatively low yields of between 5-25% of the initial starting yield [25]. One way to increase 
the purity of vesicle fractions is through sucrose gradient centrifugation, which separates 
vesicles based on their varying flotation densities. The smallest vesicles (exosomes) are 
recorded to have flotation densities of 1.08-1.22g/mL on sucrose, Optiprep or iodixanol 
gradients [26]. The advantage of such methods is that they are less prone to capture 
contaminating cell debris. The downside is that these methods are labour intensive and not 
suited for high-throughput applications. 
More rapid methods include size-exclusion chromatography (SEC) or EV precipitation. 
Precipitation exploits the differential solubility of EVs in different solvents, such as poly-
ethylene glycol (PEG) or PRotein Organic Solvent PRecipitation (PROSPR). A range of 
commercial isolation kits have recently become available that are designed to sediment 
exosomes at lower speeds by precipitation with PEG or similar substances. These include the 
Total Exosome Isolation Kit (LifeTechnologies, USA) and ExoSpin Exosome Purification 
Kit (Cell Guidance Systems, USA). As such, this method is advantageous in some respects 
because it does not require specialist equipment, minimises the risk of damage induced by 
high centrifugal force and reduces labour. However, it is comparatively expensive when 
compared with ultracentrifugation and may allow the precipitation of non-exosomal debris 
that will interfere with the detection of EV markers [27]. This will likely hinder efforts to 
standardise EV-based therapies [28]. SEC appears to be a promising method that is reported 
to enable the isolation a highly pure population of EVs within a define size-range, while not 
significantly impacting the downstream analysis of EV surface marker proteins. This method 
has been employed by Böing and colleagues who were able to isolate EVs with a diameter 
of >70 nm from platelet-free supernatant of platelet concentrates without co-isolation of 
protein aggregates [29]. The group successfully demonstrated the technique’s potential as a 
single-step unit operation for efficient EV isolation. Moreover, SEC is an established 
downstream processing technique for the purification of intracellular proteins in the 
biopharmaceutical industry, making it an established and attractive isolation method for EVs. 
However, the technique has only recently been considered for the EV isolation and additional 
investigations are required to understand the unit operations efficiency at larger scales. 
 
Other techniques which have been used in the biopharmaceutical industry for the purification 
of biologics have also been considered for the isolation of EVs; this includes tangential flow 
filtration (TFF) which has been used for isolation and concentration of EVs in conjunction 
with other process steps. Indeed, TFF has been used in conjunction with ultracentrifugation 
for isolation of therapeutic EVs in clinical trials [10, 12]. Whilst filtration (both ultra- and 
nano-filtration) are established techniques and used widely in biopharmaceutical production 
with proven scalability, current processes employing filtration for EV isolation and 
concentration requires the use of sequential filtration steps or other purification methods and 
as such, are incapable of independently isolating EVs. Nevertheless, a recent study 
demonstrated that ultrafiltration followed by liquid chromatography resulted in a significantly 
higher yield of EVs when compared with ultracentrifugation, the current gold standard for 
EV purification [30]. The combination of ultrafiltration and liquid chromatography represents 
a more capable process with respect to both scalability and isolation of EVs from more 
complex stem cell media [30].  
  
Affinity-based selection allows for the isolation of EVs based on their surface protein profile. 
This can be achieved using magnetic or non-magnetic approaches that incorporate antibodies 
raised against proteins identified on the EV membrane, such as the tetraspanin proteins CD9, 
CD63 or CD81. However, since EVs are derived from the cell membrane there is 
considerable overlap in the surface protein profiles of each and, as yet, no specific marker has 
been identified to discriminate EVs. Such methods are also typically low throughput and 
cannot be affordably scaled to produce a commercially and clinical viable product. 
 
Other technologies and appraches inspired by exosomes include exosome-mimetic 
nanovesicles which have demonstrated the ability to deliver chemotherapeutics to the tumour 
tissue after systemic administration [31]. Through the use of a serial extrusion method with 
multiple filters of reducing pore size, monocytes and macrophages were broken down to 
produce the nanovesicles. The authors suggest that such nanovesicles share similar properties 
with exosomes but have a 100-fold higher production yield [31]. This approach of using cell 
membrane-derived particles for targeted therapeutic delivery has been an increasing area of 
research focus [32]. Gao and colleagues developed a system to make cell membrane 
nanovesicles which employed nitrogen cavitation to disrupt activated neutrophils  [33]. The 
authors demonstrated the nanovesicles could selectively bind inflamed vasculature and that 
the administration of the vesicle with TPCA-1 resulted in the significant reduction of acute 
lung inflammation in mice [33]. More recently, the authors have suggested that there is a 16-
fold increase in the production of EVs via nitrogen cavitation compared to naturally secreted 
EVs and are easier to scale-up than traditional EV production methods [34]. 
 
3.2 Storage 
Despite growing interest in the study and application of EVs for diagnostic and therapeutic 
applications, little information is currently available concerning their storage. It has been 
suggested that different storage conditions may have a negative influence on the RNA 
contained within EVs as well as the overall profile of these nano-particles. Zhou and 
colleagues have previously shown that optimal recovery rates (86%) were best obtained for 
urinary exosomes if stored at -80°C in the presence of protease inhibitors such as sodium 
azide, phenylmethane sulfonyl fluoride and leupeptin [35]. The exosomes remained intact 
and functional with no significant loss of associated protein markers, even when stored at -
80°C for seven months. However, further research is required to validate these findings for 
EVs derived from stem cells. The fact that EVs appear to be stable at -80°C will also reduce 
costs associated with the specialised cryo-storage of cell-based therapies. 
 
3.3 Scalability  
Manufacturing high numbers of EVs from human primary stem cells is likely to prove a 
challenging task. This is primarily due to the fact that stem cell properties can vary if cell 
density, passage and culture conditions are not kept consistent. Stem cells lose their 
'stemness' with increasing passage and it stands to reason that the therapeutic effects of EVs 
isolated from these cells will also be heavily constrained by the number of population 
doublings the parent cell has undergone. Potency studies will be required to accurately define 
the window of passage within which stem cells generate therapeutically effective vesicles and 
if this can be enhanced through the incorporation of agonists within the culture environment. 
If scaling of EVs is for clinical and commercial purposes is to be satisfied, current large-scale 
manufacturing methods for cell expansion will need to be optimised and an optimal cell 
source identified. It may even prove necessary to genetically modify the cell source in order 
to maintain stem cell proliferation, and thereby allow production of EVs that is less restricted 
by passage. Since EVs are a cell-derived product that contains no replicative material of their 
own, it is likely changes can be made at a cellular level are not necessarily propagated within 
the EVs.  
 
Another significant challenge in the large-scale production of EVs is the inherent difficulties 
associated with their current manufacture and purification. Although a range of purification 
options are being considered (discussed above), the current production of EVs involves large-
scale cell culture in often complex media formulations, which can contain significant levels 
of unwanted proteins and other complex macromolecular contaminants. This is particularly 
the case for processes which use fetal bovine serum (FBS) or human platelet lysate (HPL). 
Whilst there is an industry-wide focus on using chemically-defined cell culture media, it is a 
significant scientific and technical challenge to adapt an existing FBS/HPL process to a 
serum-free one. .  
 
A process for optimal EV production from the cell source must also be defined, identifying 
appropriate medium compositions and reagents to facilitate both optimal EV yield and 
function. This includes understanding whether a batch, fed-batch or continuous process is 
more appropriate for EV production without impacting on cell proliferation. A range of 
different bioreactor platforms as well as the operational parameters for such systems will 
need to be considered to achieve scaling demands whilst maintaining EV function. At present, 
hollow fibre and packed-bed bioreactors have been used for the continuous production of 
highly concentrated EVs at scale. Hollow fibre reactors which apply a fibre-base cartridge 
with a molecular weight cut-off are considered advantageous as this enables the diffusion of 
nutrients and waste products while retaining the therapeutically valuable EVs [36]. However, 
stirred-tank bioreactors are also likely to be considered as a key platform for manufacture 
given the legacy of using such systems for biologics production [37] as well as the increasing 
propensity to use such platforms for adherent cell cultures in conjunction with microcarriers 
[38-40]. Stirred-tank bioreactors can be operated with spin filters to avoid the removal of 
cells/microcarriers during the process whilst facilitating the addition and removal of 
metabolites, growth factors and other secreted vesicles in a continuous fashion. Moreover, 
stirred-tank bioreactors have proven scalability and a rich heritage for the production of 
biologics, making adoption by biopharmaceutical companies which such platforms more 
likely.  
 Scalability will also be determined by the nature of the cell source itself. Whilst there is a 
trend toward stem cell-derived EVs, most of which are adherent cells by nature, there are 
other non-adherent stem cell (e.g. haematopoietic) and immunological cell types which may 
be considered for EV production and are suspension by nature, or could be genetically 
engineered to proliferate in suspension cultures. As such, platforms that are specifically 
designed for adherent cells such as hollow-fibre bioreactors will not be considered and there 
will be a focus on employing existing platforms which are used to manufacture suspension-
based processes such as stirred-tank bioreactors.  
 
3.4 Characterisation, safety and regulation 
A common challenge across the cell and gene therapy field is the lack of effective and 
reproducible potency assays. This is similarly a significant barrier to effective translation for 
EVs, whereby the lack of both in vitro and in vivo assays may hamper progress in the field. 
However, given the need for such assays, this is now a major focus across the industry and it 
is expected that significant developments will emerge as we develop a better understanding 
about the biodistribution of cells and EVs and their mode of action.  
A number of safety and regulatory requirements need to be satisfied before the 
pharmaceutical manufacturing and clinical application of EV-based therapies can be realised. 
Given the infancy of the R&D activity for EV-based therapeutics, there are understandably 
no assays for safety testing and limited information about localisation and biodistribution 
profiles. There must also be consideration of the safety of the cell source from which the EVs 
are derived. However, given the similarities with biopharmaceutical production, significant 
learning can be applied from the sector. From a clinical perspective, aside from issues 
described earlier relating to a lack of understanding of the MoA, both dose finding and 
toxicity studies need to be satisfied, and immune and tumorigenic response to EVs fully 
evaluated. From a regulatory perspective, it will be important to define whether EVs 
represent the active drug component or whether they primarily serve as the delivery vehicle 
for a drug. As such, significant improvements are required with respect to EV 
characterization and standardization. This was recently outlined in a position paper by the 
International Society for Extracellular Vesicles and the Society for Clinical Research and 
Translation of Extracellular Vesicles Singapore [41]. It is likely that EVs will be 
characterized similarly to biologics and regulated by the regulatory agencies as such [41]. 
However, the challenge remains in identifying and understanding the active ingredient or 
excipients, hence the characterization challenge. As with cell-based therapeutics, it will be 
important to engage with the regulators from the outset as it may be the case that specific EV-
based therapeutic regulations are required [41].    
 
Translational Insight 
There is a growing body of evidence demonstrating the potential of EVs for both clinical and 
diagnostics applications. However, as with the cell therapy field, it is important that 
significant emphasis is placed on understanding the fundamental MoA of EVs so as to begin 
addressing some of the characterization, standardization and manufacturing challenges. This 
also involves understanding with respect to the scalable production of both the cell source as 
well as the fundamental bioprocessing conditions required to enable the reproducible 
production and purification of therapeutically-relevant EVs. 
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